Fig. 1From: Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trialStudy design. Overall study design of the present clinical trialBack to article page